A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Palivizumab was the only approved therapy to prevent severe RSV disease in infants and young children until the approval of nirsevimab in 2023.

Doctors recommend that eligible people get vaccinated in late summer or early fall so antibodies can kick in before cases ...

RSV vaccine recommended for adults 60+ with health issues, infants under 19 months, and all healthy adults 75+. Helps prevent ...

RSV hospitalization was associated with increased risk for new CVEs and worsening of preexisting cardiovascular conditions.

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

Scientists comment on Robert F. Kennedy Jr cancelling funding for mRNA vaccines. Prof Adam Finn, Professor of Paediatrics, University of Bristol, said: ...